Abstract
Cefotiam, a new chephalosporin, was administered to 19 patients with otolaryngeal diseases with daily doses of 1, 000mg for 5 to 12 days. In acute tonsillitis, the efficacy rate was remarkably high, peritonsillar abscess significantly high, chronic otitis media remarkably high, mandibular myelitis significantly high, postoperative infection of otolaryngologic malignant cancer moderate, and postoperative maxillary cyst significantly high. The bacteriological efficacy rate of cefotiam on Gram-positive bacilli was remarkably high, on Gram-negative bacilli moderate, and on anaerobic bacilli remarkably high. No side effect was observed.
